Cargando…

Ventilator-associated pneumonia (VAP) caused by carbapenem-resistant Acinetobacter baumannii in patients with COVID-19: Two problems, one solution?

Detalles Bibliográficos
Autores principales:	Lima, William Gustavo, Brito, Júlio César Moreira, da Cruz Nizer, Waleska Stephanie
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier Ltd. 2020
Materias:	Letter to Editors
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7833701/ https://www.ncbi.nlm.nih.gov/pubmed/32758905 http://dx.doi.org/10.1016/j.mehy.2020.110139

Ejemplares similares

The effectiveness of colistin/levofloxacin compared to colistin/meropenem in the treatment of ventilator-associated pneumonia (VAP) caused by carbapenem-resistant Acinetobacter baumannii: a randomized controlled clinical trial
por: Momenzadeh, Mahnaz, et al.
Publicado: (2022)

2557. Development of Rabbit Models of Ventilator-Associated Carbapenem-Resistant Acinetobacter baumannii Pneumonia
por: Petraitis, Vidmantas, et al.
Publicado: (2023)

The potential of drug repositioning as a short-term strategy for the control and treatment of COVID-19 (SARS-CoV-2): a systematic review
por: Lima, William Gustavo, et al.
Publicado: (2020)

Comparative Respiratory Tract Microbiome Between Carbapenem-Resistant Acinetobacter baumannii Colonization and Ventilator Associated Pneumonia
por: Xiao, Tingting, et al.
Publicado: (2022)

Is Aerosalization a Problem With Carbapenem-Resistant Acinetobacter baumannii in Thailand Hospital?
por: Apisarnthanarak, Anucha, et al.
Publicado: (2016)

Ventilator-associated pneumonia (VAP) and pleural empyema caused by multidrug-resistant Acinetobacter baumannii in HIV and COVID 19 infected patient: A case report
por: Passerotto, Rosa Anna, et al.
Publicado: (2023)

Outcomes of Adjunctive Therapy with Intravenous Cefoperazone-Sulbactam for Ventilator-Associated Pneumonia Due to Carbapenem-Resistant Acinetobacter baumannii
por: Kanchanasuwan, Siripen, et al.
Publicado: (2021)

Corrigendum: Comparative respiratory tract microbiome between carbapenem-resistant Acinetobacter baumannii colonization and ventilator associated pneumonia
por: Xiao, Tingting, et al.
Publicado: (2022)

Colistin Plus Carbapenem versus Colistin Monotherapy in the Treatment of Carbapenem-Resistant Acinetobacter baumannii Pneumonia
por: Shi, HyeJin, et al.
Publicado: (2019)

Treatment of ventilator-associated pneumonia (VAP) caused by Acinetobacter: results of prospective and multicenter ID-IRI study
por: Erdem, Hakan, et al.
Publicado: (2019)

Use of a ventilator-associated pneumonia (VAP) bundle to decrease the VAP rate in Syria
por: Alsadat, R, et al.
Publicado: (2012)

ESKAPE bacteria characterization reveals the presence of Acinetobacter baumannii and Pseudomonas aeruginosa outbreaks in COVID-19/VAP patients
por: Loyola-Cruz, Miguel Ángel, et al.
Publicado: (2023)

The effect of lactulose in prevention of ventilator associated pneumonia (VAP)
por: Zvonicek, V, et al.
Publicado: (2001)

Surveillance tracheal aspirate in ventilator associated pneumonia (VAP)
por: Lampati, L, et al.
Publicado: (2001)

Quantitative proteomics to study carbapenem resistance in Acinetobacter baumannii
por: Tiwari, Vishvanath, et al.
Publicado: (2014)

Carbapenem-resistant Acinetobacter baumannii outbreak at university hospital
por: Takagi, E.H., et al.
Publicado: (2009)

Fanny pack transmission of carbapenem-resistant Acinetobacter baumannii
por: DelleFave, Amber, et al.
Publicado: (2023)

Carbapenem-resistant Acinetobacter ventilator-associated pneumonia: Clinical characteristics and outcome
por: Gurjar, Mohan, et al.
Publicado: (2013)

In vitro activity of colistin in antimicrobial combination against carbapenem-resistant Acinetobacter baumannii isolated from patients with ventilator-associated pneumonia in Vietnam
por: Le Minh, Vien, et al.
Publicado: (2015)

In vitro Activity of Colistin in Combination with Tigecycline against Carbapenem-Resistant Acinetobacter baumannii Strains Isolated from Patients with Ventilator-Associated Pneumonia
por: Cikman, Aytekin, et al.
Publicado: (2015)

Predictors of Occurrence and 30-Day Mortality for Co-Infection of Carbapenem-Resistant Klebsiella pneumoniae and Carbapenem-Resistant Acinetobacter baumannii
por: Lv, Dongmei, et al.
Publicado: (2022)

Comparison between bacteremia caused by carbapenem resistant Acinetobacter baumannii and Acinetobacter nosocomialis
por: Yang, Ya-Sung, et al.
Publicado: (2013)

Is inhaled colistin beneficial in ventilator associated pneumonia or nosocomial pneumonia caused by Acinetobacter baumannii?
por: Demirdal, Tuna, et al.
Publicado: (2016)

Acinetobacter baumannii nosocomial pneumonia: is the outcome more favorable in non-ventilated than ventilated patients?
por: Yang, Ya-Sung, et al.
Publicado: (2013)

Retrospective Assessment of Ventilator-Associated Pneumonias due to Acinetobacter baumannii in an Oncology Hospital
por: Canturan, Sevil Yesim, et al.
Publicado: (2021)

Epidemiology of ventilator associated pneumonia (vap) in patients with abdominal sepsis
por: Hom Choudhuri, A, et al.
Publicado: (2015)

Molecular Epidemiology of Carbapenem Non-Susceptible Acinetobacter baumannii in France
por: Jeannot, Katy, et al.
Publicado: (2014)

Mobile genetic elements related to carbapenem resistance in Acinetobacter baumannii
por: Pagano, Mariana, et al.
Publicado: (2016)

Seasonal Occurrence and Carbapenem Susceptibility of Bovine Acinetobacter baumannii in Germany
por: Klotz, Peter, et al.
Publicado: (2019)

Heterocyclic Diaryliodonium-Based Inhibitors of Carbapenem-Resistant Acinetobacter baumannii
por: Kumari, Pooja, et al.
Publicado: (2023)

Prognostic differences between VAP from Acinetobacter baumanii and VAP from other microorganisms
por: Di Bonito, Marianna, et al.
Publicado: (2012)

Tigecycline Versus Colistin in the Treatment of Carbapenem-resistant Acinetobacter baumannii Complex Osteomyelitis
por: Oliveira, Priscila R., et al.
Publicado: (2020)

636. Genome Epidemiology of Carbapenem-Resistant Acinetobacter baumannii (CRAb) in the United States
por: Iovleva, Alina, et al.
Publicado: (2019)

In Vitro Synergistic Activity of Antimicrobial Combinations against Carbapenem- and Colistin-Resistant Acinetobacter baumannii and Klebsiella pneumoniae
por: Mantzana, Paraskevi, et al.
Publicado: (2023)

Emergence of carbapenem-resistant Acinetobacter baumannii as the major cause of ventilator-associated pneumonia in intensive care unit patients at an infectious disease hospital in southern Vietnam
por: Nhu, Nguyen Thi Khanh, et al.
Publicado: (2014)

Efficacy of cefiderocol- vs colistin-containing regimen for treatment of bacteraemic ventilator-associated pneumonia caused by carbapenem-resistant Acinetobacter baumannii in patients with COVID-19
por: Russo, A., et al.
Publicado: (2023)

O047: The effect of active surveillance culture of carbapenem resistant Acinetobacter baumannii on the occurrence of carbapenem resistant Acinetobacter baumannii bacteremia in a single intensive care unit
por: Kim, G, et al.
Publicado: (2013)

The influence of carbapenem resistance on mortality in solid organ transplant recipients with Acinetobacter baumannii infection
por: de Gouvêa, Erika Ferraz, et al.
Publicado: (2012)

Prognostic factors associated with mortality of drug-resistant Acinetobacter baumannii ventilator-associated pneumonia
por: Inchai, Juthamas, et al.
Publicado: (2015)

The zero-VAP sophistry and controversies surrounding prevention of ventilator-associated pneumonia
por: Colombo, Sebastiano Maria, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_5sfi24torletvon9harphn9igg